Arie Belldegrun insider trades
Open-market stock purchases and sales by Arie Belldegrun, Director at UroGen Pharma Ltd, from SEC Form 4 filings since Jul 26, 2010.
Track record: 0% of 6 scored buys are up 5% or more since purchase, averaging -80%.
Companies traded
- URGN UroGen Pharma Ltd: other filings, last Jun 22, 2026
- ALLO Allogene Therapeutics, Inc: 6 buys, last Feb 2, 2026
- KRON Kronos Bio, Inc: other filings, last Jun 20, 2025
- DNA Ginkgo Bioworks Holdings, Inc: other filings, last Jun 13, 2024
- KITE Kite Pharma, Inc: 1 buy, 2 sales, last Oct 3, 2017
- ARNI Arno Therapeutics, Inc: 8 buys, last Aug 15, 2016
- NLTX Nile Therapeutics, Inc: other filings, last May 10, 2011